川宁生物(301301) - 2024 Q2 - 季度业绩预告

Financial Performance Expectations - The company expects net profit attributable to shareholders to be between 730 million and 770 million CNY for the first half of 2024, representing a year-on-year growth of 86.76% to 97.00% compared to 390.87 million CNY in the same period last year[2] - The net profit after deducting non-recurring gains and losses is also projected to be between 730 million and 770 million CNY, with a year-on-year growth of 85.95% to 96.14% compared to 392.57 million CNY last year[2] Reasons for Performance Increase - The primary reasons for the performance increase include rising market demand leading to both volume and price increases for main products, and improved production technology resulting in higher output and reduced production costs[3]